While the STEP HFpEF trial highlighted the benefits of GLP-1 receptor agonists in obesity-related HFpEF, the STEP HFpEF DM trial focused on those with comorbid diabetes and obesity, who often present with more advanced and resistant disease [24]. Here, GLP1R is linked to diabetes mellitus.